SCHEMBL1499365

SCHEMBL1499365

CCN(CC)CCCNC(=O)c1ccc(Nc2cccnc2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.44
▸ WDR77 Q9BQA1 1/20 0.44
▸ IGF1R P08069 3/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ TP53 P04637 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PTAFR P25105 1/20 0.43
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC7 Q8WUI4 1/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ HDAC10 Q969S8 1/20 0.43
▸ HDAC11 Q96DB2 1/20 0.43
▸ HDAC8 Q9BY41 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ HDAC9 Q9UKV0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12964301 0.87 PRMT5 (0.48) PRMT5WDR77TP53HTTSMN1; SMN2
SCHEMBL2453462 0.85 HDAC3 (0.53) IGF1RCYP2C19SMN1; SMN2HDAC3HDAC4
SCHEMBL1499432 0.82 HDAC6 (0.41) PRMT5WDR77IGF1RTP53HTT
SCHEMBL1499435 0.82 HDAC6 (0.41) PRMT5WDR77IGF1RTP53HTT
SCHEMBL1499693 0.82 HDAC3 (0.46) PRMT5WDR77IGF1RTP53HTT
SCHEMBL1499689 0.82 HDAC3 (0.46) PRMT5WDR77IGF1RTP53HTT
SCHEMBL1499494 0.81 PTGS2 (0.56) TP53KMT2A
SCHEMBL1499539 0.81 NAMPT (0.47) CYP2C19HTTSMN1; SMN2KMT2ANPC1
SCHEMBL1499639 0.81 MAPT (0.50) PRMT5WDR77GFERHTTSMN1; SMN2
SCHEMBL1499562 0.81 HDAC1 (0.47) PRMT5WDR77IGF1RTP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011509280-A — — 2011-03-24 — — JP claimed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 — — EP claimed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 — — WO claimed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 — — WO claimed
EP-3536691-B1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2022-10-05 — — EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 — — EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 — — EP disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 — — US disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 — — US disclosed
EP-3536691-A1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) 2019-09-11 — — EP disclosed
EP-3536691-A1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) 2019-09-11 — — EP disclosed
US-20190022037-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-01-24 — — US disclosed
US-20140155436-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2014-06-05 — — US disclosed
US-8604063-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2013-12-10 — — US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 — — US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 — — US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 — — US disclosed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 — — EP disclosed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 — — WO disclosed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190022037-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, RBM22, PRPF40A PRMT5 770/4885WDR77 1579/4885IGF1R 4219/4885
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, PRPF40A PRMT5 770/4885WDR77 1579/4885IGF1R 4219/4885
US-20140155436-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 PRMT5 550/4885WDR77 366/4885IGF1R 3832/4885
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 PRMT5 550/4885WDR77 366/4885IGF1R 3832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback